急性缺血性卒中是脑组织缺血缺氧而引起神经功能损伤的临床综合征，抗血小板治疗是缺 血性卒中预防及治疗的基础，替罗非班作为一种 GP Ⅱb/Ⅲa 受体抑制剂的新型抗血小板药物，在心血管 疾病应用已经基本成熟，但是在脑血管疾病中的应用仍处于探索阶段，具体用法用量及安全性仍有较多 争议，现就替罗非班在急性缺血性卒中治疗中的应用及研究进展进行综述。

Acute ischemic stroke is a clinical syndrome manifesting nerve function impairment caused by brain ischemia and hypoxia. Antiplatelet therapy is the basis for the prevention and treatment of acute cerebral infarction. As a novel antiplatelet drug and inhibitor of GP IIb/IIIa receptor，tirofiban has been basically mature in the treatment of cardiovascular diseases. However，application of tirofiban for cerebrovascular diseases is still in the exploratory stage，and the administration routes，dosage and safety are still controversial. This paper reviews the application and research progress of tirofiban in the treatment of acute ischemic stroke.